Vectura Group PLC (LON:VEC)‘s stock had its “buy” rating reissued by equities researchers at Peel Hunt in a research report issued to clients and investors on Tuesday. They presently have a GBX 200 ($2.47) price target on the stock. Peel Hunt’s price target indicates a potential upside of 27.06% from the stock’s current price.
Several other research firms have also recently commented on VEC. JPMorgan Chase & Co. raised their target price on shares of Vectura Group PLC from GBX 230 ($2.84) to GBX 240 ($2.96) and gave the stock an “overweight” rating in a research note on Wednesday, January 4th. Numis Securities Ltd restated a “buy” rating and issued a GBX 252 ($3.11) target price on shares of Vectura Group PLC in a research note on Wednesday, January 11th. N+1 Singer reiterated a “buy” rating and issued a GBX 202 ($2.49) price target on shares of Vectura Group PLC in a report on Wednesday, January 11th. Citigroup Inc increased their price target on shares of Vectura Group PLC from GBX 220 ($2.72) to GBX 225 ($2.78) and gave the company a “buy” rating in a report on Thursday, March 2nd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a GBX 225 ($2.78) price target on shares of Vectura Group PLC in a report on Wednesday, January 11th. Seven research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of GBX 220.29 ($2.72).
Vectura Group PLC (LON:VEC) opened at 165.20 on Tuesday. The stock’s 50 day moving average price is GBX 144.08 and its 200-day moving average price is GBX 139.84. Vectura Group PLC has a 12-month low of GBX 122.90 and a 12-month high of GBX 179.00. The firm’s market cap is GBX 949.40 million.
Your IP Address:
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.